HCPCS code C1717: Brachytherapy source, non-stranded, HDR iridium-192

Key takeaways

HCPCS code C1717 describes a brachytherapy source, non-stranded, high dose rate iridium-192, reported per source used during a procedure.

C1717 is an OPPS C-code valid only for hospital outpatient billing. It cannot be used in physician offices or ambulatory surgery centers.

Each iridium-192 source placed counts as one billable unit. Misdeclaring the source count is the most common denial trigger for this code.

Practice management software like Pabau helps radiation oncology billing teams track per-source units, attach supporting documentation, and reduce OPPS claim denials.

HCPCS code C1717 identifies a brachytherapy source that is non-stranded, high dose rate (HDR), and uses iridium-192 as the radioactive isotope. The code is reported per source, meaning each individual iridium-192 seed or capsule placed during the procedure generates one billing unit. Hospital outpatient coders working in radiation oncology departments encounter this code whenever HDR brachytherapy is delivered using a non-stranded Ir-192 source configuration. Accurate claims management software is essential for tracking per-source counts and submitting clean OPPS claims.

The official descriptor, as maintained by the Centers for Medicare and Medicaid Services (CMS), reads: Brachytherapy source, non-stranded, high dose rate iridium-192, per source. Every word in that descriptor carries billing weight. “Non-stranded” specifies the physical source configuration. “High dose rate” differentiates the delivery modality from low dose rate (LDR) brachytherapy. “Per source” sets the unit of service.

C1717 code details at a glance

The table below summarizes the administrative and technical attributes of HCPCS code C1717 as currently maintained under the CMS OPPS framework.

What does HCPCS code C1717 cover?

High dose rate brachytherapy delivers radiation from a radioactive source positioned inside or immediately adjacent to a tumor. The iridium-192 isotope is the workhorse of HDR programs worldwide. Its energy profile allows precise dose delivery through a remotely controlled afterloader, typically in one or more short treatment sessions. That differs from the continuous low-level exposure used in LDR implants.

HCPCS code C1717 covers the source itself, not the professional service or technical treatment delivery. The source is the iridium-192 capsule or seed. Separately reported CPT codes cover the treatment planning, physics work, and physician services associated with HDR brachytherapy delivery.

Common oncology indications where HDR iridium-192 brachytherapy, and therefore C1717, appears include:

• Prostate cancer (interstitial HDR brachytherapy as monotherapy or boost)
• Cervical cancer (intracavitary HDR brachytherapy)
• Breast cancer (accelerated partial breast irradiation via interstitial catheters)
• Endometrial cancer (vaginal cuff brachytherapy)
• Esophageal and bile duct cancers (intraluminal brachytherapy)
• Soft tissue sarcomas (perioperative interstitial brachytherapy)

Breast procedures often bill the delivery catheter separately from the source itself, using 19297 for interstitial catheter placement. C1717 covers each iridium-192 source loaded through that catheter.

Coverage under Medicare and most commercial payers requires documented medical necessity for brachytherapy as a treatment modality for the specific cancer type. The code itself does not convey medical necessity. The diagnosis codes on the claim and the supporting clinical record do.

Billing guidelines for HCPCS code C1717

C1717 is an OPPS C-code. This is not a technical detail to skim past. It determines where the code is valid, how it is paid, and what claim form and format apply.

The rules below reflect CMS OPPS policy. MAC-specific Local Coverage Determinations (LCDs) may add further requirements, so always check your MAC’s policies before submitting.

For teams managing high-volume outpatient billing, an outpatient procedure billing workflow reference can help enforce consistent unit-counting practices across coders. The same per-unit discipline applies to other HCPCS supply codes, such as A4774, where the billed quantity must match the documented count.

• OPPS only: C1717 is valid exclusively on UB-04 (CMS-1450) claims submitted by hospital outpatient departments. It is not valid on CMS-1500 claims from physician offices or free-standing ASCs.
• Per-source reporting: Each discrete iridium-192 source used equals one unit of service. If 12 sources are placed during a procedure, bill 12 units of C1717. The number of units must match the treatment plan and operative record.
• Revenue code: C-codes for brachytherapy sources are reported with revenue code 0274 (Medical/Surgical Supplies) or the appropriate radiation therapy supply revenue code. The applicable code depends on your MAC’s requirements. Confirm the applicable revenue code with your facility’s revenue integrity team.
• APC assignment: CMS assigns C1717 to an Ambulatory Payment Classification (APC) group under OPPS. The specific APC determines the pass-through or packaged payment status. Verify the current APC assignment in the CMS OPPS final rule for the applicable payment year.
• Modifier usage: No standard modifiers are routinely required for C1717, but payer-specific requirements vary. Review your MAC’s LCD and any applicable payer policies before adding modifiers.
• Bundling: National Correct Coding Initiative (NCCI) edits govern whether C1717 can be billed alongside certain CPT codes on the same claim date. Review NCCI tables for brachytherapy source codes when combining C1717 with treatment delivery CPT codes.

Documentation requirements for brachytherapy source non-stranded billing

Billing C1717 without adequate documentation is the fastest route to a denial or a post-payment audit finding. The medical record must support every unit of C1717 billed. HIPAA-compliant documentation practices also require that brachytherapy source records are maintained securely and retrievable for audit.

Required documentation elements include:

• Physician order: A signed physician order specifying HDR brachytherapy with iridium-192 sources.
• Treatment plan: A radiation oncologist-approved treatment plan documenting the prescribed dose, number of treatment sessions, and source placement configuration.
• Source count verification: The treatment record or source log must identify the exact number of iridium-192 sources used during the session. This is the number that drives the units billed on C1717.
• Operative / procedure note: A note from the physician or physicist documenting source placement, positioning, and any intraoperative adjustments.
• Diagnosis linkage: ICD-10-CM diagnosis codes on the claim must support medical necessity for brachytherapy for the specific cancer type. For prostate cases, the primary malignancy code, such as C61, drives the coverage determination, and every other indication follows the same rule.

Using digital forms for clinical documentation reduces transcription errors between the physics source log and the billing record. Automating the handoff from clinical documentation to coding reduces the source-count mismatches that generate most C1717 denials.

HCPCS code C1717 fee schedule and reimbursement rates

HCPCS code C1717 reimbursement flows through the CMS OPPS. Under OPPS, C-codes for brachytherapy sources have historically been eligible for pass-through payment status during defined periods. After that, they may be packaged into broader APC payments. The payment rate for any given year depends on:

• Whether C1717 holds active pass-through status for that payment year
• The APC group assignment in the annual OPPS final rule
• The geographic wage index adjustment applied by the relevant MAC
• Any outlier payments that apply based on the hospital’s cost-to-charge ratio

OPPS rates are set annually in the CMS OPPS/ASC Final Rule published each November. Specific dollar amounts cited here would be out of date by the following payment year. Always retrieve current rates from the CMS fee schedule lookup tool or the OPPS Addendum B file published with each final rule.

HDR vs LDR brachytherapy: Coding differences for high dose rate brachytherapy HCPCS

Selecting the wrong dose-rate code is one of the most consequential errors in brachytherapy billing. HDR and LDR sources have distinct physical characteristics, delivery mechanisms, and applicable HCPCS codes. Conflating them produces unbillable claims or, worse, upcoding exposure.

The table below compares the two modalities across the dimensions that drive code selection. The same precision matters in breast oncology billing, where code 19125 depends on matching the radiological marker documented in the operative note.

Related HCPCS codes for brachytherapy sources

C1717 belongs to a family of C-codes that cover brachytherapy sources by isotope, configuration (stranded vs. non-stranded), and dose rate. Selecting the correct code requires matching all three variables to the source actually used. The IVF procedure coding reference illustrates the same principle in reproductive medicine. Procedure codes are specific to the exact material or technique used, not a general category. Use the table below to distinguish C1717 from its closest siblings.

C1717 vs C1719 is the most common confusion point. Both codes cover non-stranded iridium-192 sources. The distinction is dose rate. C1717 is high dose rate. C1719 is non-high dose rate.

Confirm the dose rate classification with the radiation oncology physics team before code selection, since the procedure schedule name alone does not confirm it. For a broader reference on CCSD and outpatient procedure code families, see Pabau’s CCSD procedure code reference.

Coverage and medical necessity criteria for brachytherapy billing guidelines

HCPCS code C1717 does not itself establish coverage. Payer coverage depends on whether brachytherapy is medically necessary for the specific diagnosis billed. Medicare processes C1717 under OPPS. Commercial payers apply their own clinical policy bulletins.

Medicare: MAC-issued LCDs govern brachytherapy coverage. Coverage criteria typically require documentation of a primary malignancy for which brachytherapy has demonstrated clinical efficacy. They also require a physician-certified treatment plan and appropriate specialty billing under radiation oncology. The claim’s ICD-10-CM diagnosis code must map to a covered indication under the applicable LCD.

Commercial payers: Many large commercial plans publish clinical policy bulletins for brachytherapy. Aetna’s Clinical Policy Bulletin 0371, for example, lists HDR brachytherapy with iridium-192 as medically necessary for prostate, cervical, and breast cancers. That coverage applies when clinical criteria are met. Commercial payer policies change; always confirm current criteria before treatment.

Non-covered situations: C1717 claims are routinely denied when:

• The diagnosis code reflects a non-covered indication (benign conditions, off-label uses not supported by the LCD)
• Brachytherapy is used as an experimental or investigational approach per payer policy
• The treatment setting is not a hospital outpatient department (physician office or ASC submission)
• Prior authorization was not obtained where required by the payer

Common billing errors with HCPCS code C1717 and how to avoid them

Most C1717 denials trace back to four root causes. Understanding them before a claim is submitted is more efficient than working a denial queue afterward. Review medical forms standardization for a broader look at how structured documentation reduces coding errors of exactly this kind.

• Source count mismatch: The units billed on C1717 do not match the number of sources documented in the physics log or procedure note. This is the single most auditable error in HDR billing. Establish a workflow that routes the source log directly to coding before claim submission.
• Wrong code for dose rate: Using C1717 when the source was non-HDR iridium-192 (C1719) instead, or vice versa. Confirm dose rate with the radiation oncology physicist, not from the procedure schedule name alone.
• Wrong setting on claim form: Submitting C1717 on a CMS-1500 form from a physician office. C-codes are valid on UB-04 forms only. If a hospital-based physician practice submits separately, the source code goes on the facility claim.
• Missing or inadequate diagnosis linkage: Billing C1717 with a vague or non-covered ICD-10-CM diagnosis. The primary malignancy code and any relevant secondary codes must be present and must match the covered indication in the applicable LCD or commercial policy.

A fifth error pattern involves billing C1719 (non-HDR iridium-192) when the source used was HDR iridium-192, which calls for C1717 instead. Confirm the dose rate with the physics record before choosing between the two codes.

The same specificity principle governs add-on coding elsewhere, such as 17315 for additional Mohs surgery tissue blocks. The most specific valid code is always the right code.

How Pabau supports HCPCS code C1717 billing accuracy

Outpatient radiation oncology teams billing C1717 juggle three separate records: a physics log, an operative note, and the billing system itself. When those records sit in different places, the detail that separates C1717 from C1719 or C1716 often gets lost in the handoff.

That gap drives many C1717 denials. Practice management software like Pabau keeps that record connected. Treatment notes, consent documentation, and code-to-procedure association can sit against one patient record.

That means the physics and operative detail behind a C1717 claim is already there when staff prepare it. Nobody has to chase it down from radiation oncology after the fact.

Pabau’s claims and billing tools don’t submit hospital OPPS claims directly. Its role is keeping that documentation trail audit-ready for the practice’s existing billing workflow. The same document-to-code discipline applies outside radiation oncology. A practice using regenerative medicine EMR software to track injection-specific billing codes faces that same need. So does an OB/GYN practice documenting procedure-specific care before a claim goes out.

Reduce OPPS claim denials with Pabau

Pabau's claims management tools help hospital outpatient billing teams track per-source units, attach supporting documentation, and submit clean HCPCS claims the first time.

Book a demo

Conclusion

Getting C1717 right comes down to one habit: matching the claim to the physics record before it goes out. Confirm the isotope, the dose rate, and the source count every time. Any one of the three can shift the code to C1719, C1716, or a denial.

That discipline is what separates a clean OPPS claim from a source-count denial or an audit flag. A hospital outpatient program that keeps the physics, operative, and billing records connected catches the mismatch before submission instead of after a 90-day denial cycle.

Book a demo to see how Pabau keeps that documentation trail connected for hospital outpatient billing teams handling brachytherapy source claims.

Continue your research

Coding another OPPS supply item? E0197 walks through billing rules for air pressure pad mattresses in outpatient and home health claims.

Billing a different per-unit HCPCS supply code? B4176 covers per-unit reporting for parenteral nutrition solution claims.

Coding recurring dialysis supply claims? A4750 covers blood tubing billing rules for hemodialysis claims.

Frequently asked questions